Tag #Pharmaceutical Transparency

What is the immediate impact of Novo Nordisk's failure to disclose millions of pounds in payments on public trust in the pharmaceutical industry?

Novo Nordisk, the maker of Wegovy, Ozempic, and Saxenda, failed to disclose millions of pounds in payments to healthcare groups and patient organizations. This includes £1.2 million in unreported payments and misattributed funds, such as £338,435 mistakenly listed for a different organization. A recent investigation uncovered serious breaches of industry code.